GlassScriptPhysician profile
Lauren Wheeler
NPI 1386091775
$25,322.91
in general payments reported to CMS, 2019-2025
34 companies · $3,950 in 2025
The $3,950 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,964 · 2022: $5,949 · 2023: $5,492 · 2024: $4,969 · 2025: $3,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,265.37 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,864.94 | 2021-2025 | Krystexxa, Enbrel, Tavneos |
| Abbvie INC. | $4,022.00 | 2021-2025 | |
| Ucb, INC. | $2,267.83 | 2021-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $1,861.27 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $1,741.53 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,661.93 | 2021-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $1,567.37 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Horizon Therapeutics Plc | $1,495.99 | 2021-2023 | Krystexxa |
| Lilly USA, LLC | $783.31 | 2021-2025 | Taltz |
| Genentech USA, INC. | $744.84 | 2021-2025 | Actemra, Rituxan, Gazyva |
| E.R. Squibb & Sons, L.L.C. | $584.83 | 2021-2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.46 | 2021-2025 | Ofev, Cyltezo |
| Pfizer INC. | $537.01 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $498.42 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $473.32 | 2021-2025 | Tymlos |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $398.87 | 2021-2025 | Acthar |
| Allergan, INC. | $251.59 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $158.30 | 2024-2025 | Strensiq |
| Daiichi Sankyo INC. | $150.21 | 2021-2024 | Injectafer |
| Genzyme Corporation | $139.59 | 2021-2025 | |
| Sandoz INC. | $109.73 | 2023-2024 | Hyrimoz |
| Janssen Scientific Affairs, LLC | $98.05 | 2021-2025 | Tremfya |
| Pacira Therapeutics, INC. | $54.92 | 2021 | |
| Organon LLC | $42.93 | 2022-2025 | Hadlima, Renflexis |
| Mylan Institutional INC. | $36.70 | 2023 | Hulio |
| Sobi, INC | $35.19 | 2025 | |
| Depuy Synthes Sales INC. | $35.02 | 2025 | Monovisc |
| Aurinia Pharma U.S., INC. | $19.78 | 2024 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $19.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.05 | 2023 | Quviviq |
| Bioventus LLC | $17.58 | 2023 | Durolane |
| Alvogen INC | $17.34 | 2024 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $16.43 | 2021 | |
| Tersera Therapeutics LLC | $14.13 | 2025 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.